Editorials: Cell Cycle Features

p53 and cancer stem cells: The mevalonate connexion

Volume 11, Issue 14   July 15, 2012
Pages 2583 - 2584
http://dx.doi.org/10.4161/cc.21092
Authors: Christophe Ginestier, Emmanuelle Charafe-Jauffret and Daniel Birnbaum

View affiliations

Abstract:
Comment on: Freed-Pastor WA, et al. Cell 2012; 148:244-58 and Ginestier C, et al. Stem Cells 2012; 1327-37.

Editorials: Cell Cycle Features to:
WA Freed-Pastor, H Mizuno, X Zhao, A Langerød, SH Moon, R Rodriguez-Barrueco, A Barsotti, A Chicas, W Li, A Polotskaia, MJ Bissell, TF Osborne, B Tian, SW Lowe, JM Silva, AL Børresen-Dale, AJ Levine, J Bargonetti, C Prives. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148: 244-258
PMID: 22265415 DOI: 10.1016/j.cell.2011.12.017
and
C Ginestier, F Monville, J Wicinski, O Cabaud, N Cervera, E Josselin, P Finetti, A Guille, G Larderet, P Viens, S Sebti, F Bertucci, D Birnbaum, E Charafe-Jauffret. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012; 30: 1327-37
PMID: 22605458 DOI: 10.1002/stem.1122

Received: June 8, 2012; Accepted: June 11, 2012

Preview:



Advertisements